The future of PARP inhibitors in prostate cancer
Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain
2 Jul 2020
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
30 Jun 2020
ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer
Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany
24 Jun 2020
FGFR inhibitors in bladder cancer: Testing, screening and highlights from ASCO 2...
Prof Robert Huddart and Dr Ignacio Durán
15 Jun 2020
CTC count as a prognostic marker for androgen deprivation plus orteronel or bica...
Dr Amir Goldkorn - Keck School of Medicine of USC, Los Angeles, USA
12 Jun 2020
Updated results from KEYNOTE-426 for metastatic kidney cancer
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
12 Jun 2020
HCRN GU16-260: Nivolumab and salvage nivolumab ipilimumab in treatment-naïve p...
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
12 Jun 2020
Comment: JAVELIN-100 for metastatic urothelial cancer
Dr Elizabeth Plimack - Fox Chase Cancer Center, Philadelphia, USA
12 Jun 2020
PARP inhibitors in prostate cancer: Choices of tests and how to test?
Dr Kim Chi and Dr Alexander Wyatt
11 Jun 2020
ASCO 2020 prostate cancer highlights
Prof Karim Fizazi, Prof Axel Merseburger, Dr Kim Chi and Prof Amit Bahl
10 Jun 2020
Perioperative novel systemic immunotherapy-based approaches in urinary cancers
Dr Shilpa Gupta - Cleveland Clinic, Cleveland, USA
9 Jun 2020
ASCO 2020: Updates in renal cancer
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
5 Jun 2020
